A second article in a series of four planned has just been published. It is about the health economics of treatment discontinuation. Led by Giovany Orozco-Leal the article can be…
It is over a decade ago now but I still recall vividly when, at the first meeting of what would become the aHUS alliance in 2013, the representative from Italy…
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question to our expert. Can a complement inhibitor be stopped…
For aHUS patients stopping eculizumab (or even Ravulizumab) treatment is an important but emotive issue. Having had the treatment when seriously ill and then recovered, no one wants to go…
There are two sets of patient groups affected by an aHUS name change. Those who have had it and already been diagnosed with it and those who have not yet…
What’s new in aHUS research? Quite a bit, if you consider that over four dozen publications have just been added to our aHUS-specific ‘Virtual Library’. There’s a reason we’re so…
This is a plain language summary of the final article to be published about Stopping Eculizumab Treatment Safely Clinical Trial. The aim of the Stopping Eculizumab Treatment Safely atypical haemolytic…
From start to finish it’s been a busy year in the global ‘aHUS space’ yet before we say hello to 2026 issued our December 2025 edition of The aHUS Global…